1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 MEDIMPACT HEALTHCARE Case No.: 19-cv-1865-GPC (DEB) SYSTEMS, INC., et al., 12 ORDER: Plaintiffs, 13 v. (1) REGARDING PLAINTIFFS’ 14 MOTION FOR PROTECTIVE IQVIA INC., et al., 15 ORDER; AND Defendants. (2) GRANTING PLAINTIFFS’ 16 MOTION TO FILE DOCUMENTS 17 UNDER SEAL
18 [DKT. NOS. 151, 157] 19 20 I. BACKGROUND 21 This is a suit for misappropriation of trade secrets. In their Amended Complaint, 22 Plaintiffs allege IMS Health (now Defendants IQVIA Inc., IQVIA Ltd., and IQVIA AG) 23 wrongfully obtained and used data from Plaintiffs’ pharmacy benefits management 24 (“PBM”) platform. Dkt. No. 93. 25 Before the Court is the parties’ dispute over whether to include an “Attorney’s Eyes 26 Only – Outside Counsel Only” confidentiality category in a protective order. Dkt. No. 27 151-1 at 4. Plaintiffs seek the additional confidentiality category to prevent Defendants’ 28 in-house counsel from accessing their trade secrets and source codes. Id. Defendants 1 contend that the following in-house attorneys and staff should have access to this 2 information: Harvey Ashman, Laura Kibbe, Maureen Nakly, and Lisa Katz (collectively 3 referred to as “Designees”).1 The parties briefed the issue. Dkt. Nos. 151, 153, 159.2 4 For the foregoing reasons, the Court GRANTS Plaintiffs’ request to preclude access 5 by Mr. Ashman and DENIES Plaintiffs’ request as to the remaining Designees. 6 II. LEGAL STANDARDS 7 “Rule 26(c) confers broad discretion on the trial court to decide when a protective 8 order is appropriate and what degree of protection is required.” GXP Capital, LLC v. 9 Argonaut EMS, No. 17-cv-2283-GPC (BLM), 2018 U.S. Dist. LEXIS 102581, at *7 (S.D. 10 Cal. June 19, 2018) (citing Seattle Times Co. v. Rhinehart, 467 U.S. 20, 36 (1984)). To 11 resolve disputes over protective orders “distinguishing between outside and in-house 12 counsel,” courts balance the conflicting interests of the parties involved. Brown Bag 13 Software v. Symantec Corp., 960 F.2d 1465, 1470 (9th Cir. 1992). On one end of the 14 balancing scale is the risk of inadvertent disclosure of the producing party’s confidential 15 information; on the other end is the risk that restricting access to confidential information 16 might impair the requesting party’s ability to litigate the case. Kaseberg v. Conaco, No. 17 15-cv-01637-JLS (DHB), 2016 WL 3997600, at *13 (S.D. Cal. July 26, 2016). 18 When determining whether in-house counsel may have access to confidential 19 information, the Court must “examine factually all the risks and safeguards surrounding 20 inadvertent disclosure by any counsel. . . .” Brown Bag Software, 960 F.2d at 1470 21 (emphasis in original). A crucial factor is “whether in-house counsel was involved in 22 23 24 1 In their Opposition, Defendants agreed to remove Adam Shanti from the list of in- 25 house counsel who may receive access to Plaintiff’s trade secrets and source codes. Dkt. No. 153 at 9 n.3. 26
27 2 Defendants request an evidentiary hearing. Dkt. No. 153 at 13. The Court finds that the briefing, declarations, and exhibits submitted by the parties provide all the information 28 1 competitive decision-making; that is, advising on decisions about pricing or design made 2 in light of similar or corresponding information about a competitor.” Id. (internal citation 3 and quotations omitted). Also, the “nature of the claims and of a party’s opportunity to 4 develop its case through alternative discovery procedures factors into decisions on the 5 propriety of such protective orders.” Id. 6 At the outset, Plaintiffs bear the burden of showing that a risk of inadvertent 7 disclosure exists (i.e., that Defendants’ Designees participate in competitive decision- 8 making). See ODS Techs., L.P. v. Magna Entm’t Corp., 583 F. Supp. 2d 1141, 1144–45 9 (C.D. Cal. 2008) (“[D]efendants must show that [plaintiff’s in-house counsel designated 10 attorney’s] relationship to [plaintiff] is such that she gives advice or participates in 11 [competitive decision-making].”). If the Designees are involved in competitive decision- 12 making, the burden shifts to Defendants to demonstrate actual prejudice to their case if 13 access is not granted. See id. 14 III. DISCUSSION 15 Plaintiffs assert that their trade secrets and source codes are proprietary, closely 16 guarded, and that their disclosure to Defendants’ in-house counsel will result in competitive 17 harm. Dkt. No. 151-1 at 4. In response, Defendants argue that there is no risk of competitive 18 harm because: (1) the parties are not competitors, and (2) the Designees are not competitive 19 decisionmakers. Dkt. No. 153 at 4. 20 The Court accepts Plaintiffs’ assertion that their trade secrets are proprietary, and 21 prejudice will result if they are disclosed to their competitors. Defendants’ argument that 22 the parties are not competitors is in dispute and goes to the merits of this case. The Court, 23 therefore, is in no position to make a finding on this ultimate issue at this early stage of the 24 litigation. Plaintiffs sued Defendants for misappropriation of trade secrets indicating that 25 Plaintiffs believe (be it meritorious or not) that the parties have at least some overlapping 26 interests in the same industry. See Vampire Family Brands, LLC v. Applebees Restaurants, 27 LLC, No. 19-cv-09222-DOC-ADSx, 2020 WL 7380143, at *2 (C.D. Cal. Sept. 30, 2020) 28 (rejecting similar argument that parties are not in competition because “one of Plaintiff’s 1 claims is nevertheless based on its allegation that Defendants’ marketing of a particular 2 cocktail ‘closely resembles’ one of Plaintiff’s own cocktails”). Additionally, the Court 3 notes that both parties operate in the pharmaceutical management industry and that 4 Defendants could enter into the PBM space in the future, even if they are not directly 5 involved in that space now. Accord Nutratech, Inc. v. Syntech (SSPF) Int’l, Inc., 242 F.R.D. 6 552, 555 (C.D. Cal. 2007) (finding good cause for a protective order even though 7 “[plaintiff] asserts that it currently sells to different buyers, this assertion does not mean 8 that [plaintiff] will not choose to become a direct competitor of [defendant] in the future”). 9 The Court, therefore, finds that Plaintiffs have adequately established potential harm 10 should their confidential information become inadvertently disclosed. 11 Next, the Court will balance the conflicting interests of the parties involved based 12 on the Brown Bag factors on an attorney-by-attorney basis. Brown Bag Software, 960 F.2d 13 at 1470; see also U.S. Steel Corp. v. U.S., 730 F.2d 1465, 1468 (Fed. Cir. 1984) (“Whether 14 an unacceptable opportunity for inadvertent disclosure exists, however, must be 15 determined . . . by the facts on a counsel-by-counsel basis. . . .”). 16 Plaintiffs claim each Designee is a competitive decisionmaker because “knowledge 17 of MedImpact’s trade secrets will inherently put these . . . individuals in conflicted 18 positions.” Dkt. No. 151-1 at 10–12. Plaintiffs argue disclosure to these individuals would, 19 therefore, result in “far too great a risk . . . of inadvertent disclosure.” Id. at 13. Specifically, 20 Plaintiffs present evidence showing Mr. Ashman’s position at IQVIA, Dkt. No. 151-9 at 2, 21 his former testimony as an IMS Health in-house lawyer, Dkt. No. 151- 8 at 5, and attach 22 Mses. Nakly, Kibbe, and Katz’s LinkedIn profiles listing their employment history, 23 Dkt. Nos. 151-11–151-13.
Free access — add to your briefcase to read the full text and ask questions with AI
1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 MEDIMPACT HEALTHCARE Case No.: 19-cv-1865-GPC (DEB) SYSTEMS, INC., et al., 12 ORDER: Plaintiffs, 13 v. (1) REGARDING PLAINTIFFS’ 14 MOTION FOR PROTECTIVE IQVIA INC., et al., 15 ORDER; AND Defendants. (2) GRANTING PLAINTIFFS’ 16 MOTION TO FILE DOCUMENTS 17 UNDER SEAL
18 [DKT. NOS. 151, 157] 19 20 I. BACKGROUND 21 This is a suit for misappropriation of trade secrets. In their Amended Complaint, 22 Plaintiffs allege IMS Health (now Defendants IQVIA Inc., IQVIA Ltd., and IQVIA AG) 23 wrongfully obtained and used data from Plaintiffs’ pharmacy benefits management 24 (“PBM”) platform. Dkt. No. 93. 25 Before the Court is the parties’ dispute over whether to include an “Attorney’s Eyes 26 Only – Outside Counsel Only” confidentiality category in a protective order. Dkt. No. 27 151-1 at 4. Plaintiffs seek the additional confidentiality category to prevent Defendants’ 28 in-house counsel from accessing their trade secrets and source codes. Id. Defendants 1 contend that the following in-house attorneys and staff should have access to this 2 information: Harvey Ashman, Laura Kibbe, Maureen Nakly, and Lisa Katz (collectively 3 referred to as “Designees”).1 The parties briefed the issue. Dkt. Nos. 151, 153, 159.2 4 For the foregoing reasons, the Court GRANTS Plaintiffs’ request to preclude access 5 by Mr. Ashman and DENIES Plaintiffs’ request as to the remaining Designees. 6 II. LEGAL STANDARDS 7 “Rule 26(c) confers broad discretion on the trial court to decide when a protective 8 order is appropriate and what degree of protection is required.” GXP Capital, LLC v. 9 Argonaut EMS, No. 17-cv-2283-GPC (BLM), 2018 U.S. Dist. LEXIS 102581, at *7 (S.D. 10 Cal. June 19, 2018) (citing Seattle Times Co. v. Rhinehart, 467 U.S. 20, 36 (1984)). To 11 resolve disputes over protective orders “distinguishing between outside and in-house 12 counsel,” courts balance the conflicting interests of the parties involved. Brown Bag 13 Software v. Symantec Corp., 960 F.2d 1465, 1470 (9th Cir. 1992). On one end of the 14 balancing scale is the risk of inadvertent disclosure of the producing party’s confidential 15 information; on the other end is the risk that restricting access to confidential information 16 might impair the requesting party’s ability to litigate the case. Kaseberg v. Conaco, No. 17 15-cv-01637-JLS (DHB), 2016 WL 3997600, at *13 (S.D. Cal. July 26, 2016). 18 When determining whether in-house counsel may have access to confidential 19 information, the Court must “examine factually all the risks and safeguards surrounding 20 inadvertent disclosure by any counsel. . . .” Brown Bag Software, 960 F.2d at 1470 21 (emphasis in original). A crucial factor is “whether in-house counsel was involved in 22 23 24 1 In their Opposition, Defendants agreed to remove Adam Shanti from the list of in- 25 house counsel who may receive access to Plaintiff’s trade secrets and source codes. Dkt. No. 153 at 9 n.3. 26
27 2 Defendants request an evidentiary hearing. Dkt. No. 153 at 13. The Court finds that the briefing, declarations, and exhibits submitted by the parties provide all the information 28 1 competitive decision-making; that is, advising on decisions about pricing or design made 2 in light of similar or corresponding information about a competitor.” Id. (internal citation 3 and quotations omitted). Also, the “nature of the claims and of a party’s opportunity to 4 develop its case through alternative discovery procedures factors into decisions on the 5 propriety of such protective orders.” Id. 6 At the outset, Plaintiffs bear the burden of showing that a risk of inadvertent 7 disclosure exists (i.e., that Defendants’ Designees participate in competitive decision- 8 making). See ODS Techs., L.P. v. Magna Entm’t Corp., 583 F. Supp. 2d 1141, 1144–45 9 (C.D. Cal. 2008) (“[D]efendants must show that [plaintiff’s in-house counsel designated 10 attorney’s] relationship to [plaintiff] is such that she gives advice or participates in 11 [competitive decision-making].”). If the Designees are involved in competitive decision- 12 making, the burden shifts to Defendants to demonstrate actual prejudice to their case if 13 access is not granted. See id. 14 III. DISCUSSION 15 Plaintiffs assert that their trade secrets and source codes are proprietary, closely 16 guarded, and that their disclosure to Defendants’ in-house counsel will result in competitive 17 harm. Dkt. No. 151-1 at 4. In response, Defendants argue that there is no risk of competitive 18 harm because: (1) the parties are not competitors, and (2) the Designees are not competitive 19 decisionmakers. Dkt. No. 153 at 4. 20 The Court accepts Plaintiffs’ assertion that their trade secrets are proprietary, and 21 prejudice will result if they are disclosed to their competitors. Defendants’ argument that 22 the parties are not competitors is in dispute and goes to the merits of this case. The Court, 23 therefore, is in no position to make a finding on this ultimate issue at this early stage of the 24 litigation. Plaintiffs sued Defendants for misappropriation of trade secrets indicating that 25 Plaintiffs believe (be it meritorious or not) that the parties have at least some overlapping 26 interests in the same industry. See Vampire Family Brands, LLC v. Applebees Restaurants, 27 LLC, No. 19-cv-09222-DOC-ADSx, 2020 WL 7380143, at *2 (C.D. Cal. Sept. 30, 2020) 28 (rejecting similar argument that parties are not in competition because “one of Plaintiff’s 1 claims is nevertheless based on its allegation that Defendants’ marketing of a particular 2 cocktail ‘closely resembles’ one of Plaintiff’s own cocktails”). Additionally, the Court 3 notes that both parties operate in the pharmaceutical management industry and that 4 Defendants could enter into the PBM space in the future, even if they are not directly 5 involved in that space now. Accord Nutratech, Inc. v. Syntech (SSPF) Int’l, Inc., 242 F.R.D. 6 552, 555 (C.D. Cal. 2007) (finding good cause for a protective order even though 7 “[plaintiff] asserts that it currently sells to different buyers, this assertion does not mean 8 that [plaintiff] will not choose to become a direct competitor of [defendant] in the future”). 9 The Court, therefore, finds that Plaintiffs have adequately established potential harm 10 should their confidential information become inadvertently disclosed. 11 Next, the Court will balance the conflicting interests of the parties involved based 12 on the Brown Bag factors on an attorney-by-attorney basis. Brown Bag Software, 960 F.2d 13 at 1470; see also U.S. Steel Corp. v. U.S., 730 F.2d 1465, 1468 (Fed. Cir. 1984) (“Whether 14 an unacceptable opportunity for inadvertent disclosure exists, however, must be 15 determined . . . by the facts on a counsel-by-counsel basis. . . .”). 16 Plaintiffs claim each Designee is a competitive decisionmaker because “knowledge 17 of MedImpact’s trade secrets will inherently put these . . . individuals in conflicted 18 positions.” Dkt. No. 151-1 at 10–12. Plaintiffs argue disclosure to these individuals would, 19 therefore, result in “far too great a risk . . . of inadvertent disclosure.” Id. at 13. Specifically, 20 Plaintiffs present evidence showing Mr. Ashman’s position at IQVIA, Dkt. No. 151-9 at 2, 21 his former testimony as an IMS Health in-house lawyer, Dkt. No. 151- 8 at 5, and attach 22 Mses. Nakly, Kibbe, and Katz’s LinkedIn profiles listing their employment history, 23 Dkt. Nos. 151-11–151-13. 24 Defendants respond that the Designees are not competitive decisionmakers. 25 Dkt. No. 153 at 9–12. Defendants submitted a declaration from each Designee containing 26 identical assertions regarding duties they do not perform: 27 • [They] do not make any IQVIA decisions regarding business issues like 28 pricing, product design or product development. 1 • [They are] not . . . involved in any discussions at IQVIA about the design of IQVIA’s products or services, in light of the design, features, functions or 2 other details of a competitor’s products or services. 3 • [They are] not . . . involved in any IQVIA assessments of competitive product 4 services. 5 • [They are] not . . . responsible for constructing go-to-market strategies as 6 against IQVIA competitors. 7 • [They are] not . . . responsible for pricing decisions at IQVIA. 8 • [They are] not . . . responsible for setting the economic terms of IQVIA 9 intellectual property licenses. 10 11 Dkt. Nos. 153-2 at 3–4; 153-3 at 3–4; 153-4 at 2–3; 153-4 at 3. Further, Defendants describe 12 safeguards in place to prevent inadvertent disclosures of information in possession of their 13 in-house counsel, including secure offices, restricted computer storage, and a secure third- 14 party vendor platform to host the document repository. See, e.g., Dkt. No. 153-3 at 4. 15 The Court evaluates each Designee in turn. 16 Harvey Ashman 17 Mr. Ashman’s duties involve at least some of the competitive decision-making 18 described in Brown Bag. Compare Dkt. Nos. 151-9 at 2 (speaker profile from “text IQ” 19 website stating Mr. Ashman is IQVIA’s current senior vice president and deputy general 20 counsel), and 153-2 at 2–4 (Mr. Ashman describing his roles as “providing advice in 21 connection with potential or actual infringement or non-compliance issues” and 22 “intellectual property, data protection and information security, privacy, information 23 governance, antitrust, contracting, compliance, and licensing” issues, as well as “deciding 24 whether a competitor should receive a license to access [certain] IQVIA data”), with Brown 25 Bag Software, 960 F.2d at 1471 (finding in-house counsel was a competitive decisionmaker 26 where he “was responsible for advising his employer on a gamut of legal issues, including 27 contracts, marketing, and employment”). Therefore, having reviewed Mr. Ashman’s 28 1 affidavit, Plaintiff’s exhibits, and the parties’ arguments, the Court concludes that 2 Mr. Ashman should not have access to Plaintiffs’ trade secrets and source codes. 3 The Court further finds that denying Mr. Ashman access to Plaintiffs’ trade secrets 4 and source codes will not significantly prejudice Defendants. Unlike Brown Bag and Mad 5 Catz Interactive, Inc. v. Razor USA, Ltd., Case No. 13-cv-2371-GPC (JLB), 2014 WL 6 4161713) (S.D. Cal. Aug. 9, 2017) (cited by Defendants), Mr. Ashman is neither counsel 7 of record nor lead trial counsel. Prejudice to Defendants is also minimized because 8 Mr. Ashman will not be denied access to all discovery, just Plaintiffs’ trade secrets and 9 source codes. Lastly, and as discussed below, the Court is allowing three of Defendants’ 10 in-house Designees access to Plaintiffs’ confidential information. Those Designees will be 11 available to assist outside counsel. Accordingly, the Brown Bag factors support denying 12 Mr. Ashman access to Plaintiffs’ trade secrets and source codes. 13 Maureen Nakly, Laura Kibbe, Lisa Katz 14 With respect to Mses. Nakly, Kibbe, and Katz, the Court has reviewed their 15 declarations and the parties’ exhibits and finds no basis to conclude that they are 16 competitive decisionmakers. See Dkt. Nos. 151-11–151-13; 153-3–153-5. See Javo 17 Beverage Co. v. California Extraction Ventures, Inc., No. 19-cv-1859-CAB (WVG), 2020 18 WL 2062146, at *2 (S.D. Cal. Apr. 29, 2020) (“[U]nrebutted statements made by counsel 19 asserting that he does not participate in competitive decision-making, which the court has 20 no reason to doubt, form a reasonable basis to conclude that counsel is isolated from 21 competitive decision-making.”) (citing Matsushita Elec. Indus. Co. v. United States, 929 22 F.2d 1577, 1580 (Fed. Cir. 1991)); cf. U.S. Steel Corp. v. U.S., 730 F.2d at 1469 (“[S]tatus 23 as in-house counsel cannot alone create that probability of serious risk to confidentiality 24 and cannot therefore serve as the sole basis for denial of access.”). Because they are not 25 competitive decisionmakers, and because they have safeguards in place to protect against 26 further disclosure of Plaintiffs’ trade secrets and source codes, the Court finds that the 27 Brown Bag factors do not support denying Mses. Nakly, Kibbe, or Katz access to any of 28 the discovery generated in this case. 1 IV. MOTION TO SEAL 2 Plaintiffs request sealing Exhibit 1 to their Reply. Dkt. No. 157. Plaintiffs assert that 3 || this exhibit is an excerpt from a confidential arbitration proceeding. Jd. at 3. Good cause 4 || appearing, the Court GRANTS the Motion to Seal and orders Exhibit 1 be filed under seal. 5 Kamakana v. City & County of Honolulu, 447 F.3d 1172, 1179-80 (9th Cir. 2006) 6 || (“[A] particularized showing . . . under the ‘good cause’ standard of Rule 26(c) will suffice 7 warrant preserving the secrecy of sealed discovery material attached to non-dispositive 8 || motions.”) (internal citations, quotations, and edits omitted). 9 Vv. CONCLUSION 10 The Court GRANTS Plaintiffs’ Motion for a protective order precluding access to 11 Ashman and DENIES the Motion as to Mses. Kibbe, Katz, and Nakly. The Court 12 Ildirects the parties to meet and confer and jointly submit (by email to 13 || efile _butcher@casd.uscourts.gov) a proposed protective order consistent with this order on 14 |! or before February 11, 2021. The document lodged at Dkt. No. 158 SHALL BE FILED 15 || UNDER SEAL. 16 IT IS SO ORDERED. 17 ||Dated: February 3, 2021 — 18 □□ Sapo 19 Honorable Daniel E. Butcher United States Magistrate Judge 20 21 22 23 24 25 26 27 28